Eli Lilly and Company (LLY)
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Options Bulls Target Eli Lilly Stock After Beat-and-Raise
Eli Lilly And Co (NYSE:LLY) surpassed top- and bottom-line expectations for the second quarter, and lifted its full-year revenue outlook by $3 billion amid strong sales of weight loss drug and diabetes drugs Zepbound and Mounjaro.
Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $3.92 per share, beating the Zacks Consensus Estimate of $2.64 per share. This compares to earnings of $2.11 per share a year ago.
Eli Lilly Stock Soars as Mounjaro, Zepbound Power Earnings Beat, Guidance Boost
Eli Lilly (LLY) shares surged higher in premarket trading Thursday after the drugmaker's second-quarter earnings came in well above analysts' estimates and it raised its full-year revenue and profit guidance.
Eli Lilly Surges On Strong Earnings As Mounjaro And Zepbound Sales Soar
Pharma titan Eli Lilly on Thursday reported strong demand for its weight loss and diabetes drugs Zepbound and Mounjaro, smashing analysts' expectations in the face of growing competition in the lucrative weight loss drug market as it struggles to boost supplies and tackle shortages.
Blockbuster Drugs Drive Eli Lilly's Strong Q2 Performance
Eli Lilly reports Q2 EPS of $3.92, exceeding expectations. Revenue reaches $11.30 billion, driven by strong drug sales.
Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
Eli Lilly reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. The drugmaker now expects full-year adjusted earnings of $16.10 to $16.60, up from a previous guidance of $13.50 to $14 per share.
Eli Lilly's stock leaps after big earnings beat, boosted by strength in Mounjaro and Zepbound sales
Shares of Eli Lilly & Co. LLY, -2.65% shot up 8.5% in premarket trading Thursday, after the drug maker reported second-quarter earnings that rose well above forecasts, boosted by strength in its diabetes and obesity treatments, Mounjaro and Zepbound and by higher prices. Net income jumped to $2.97 billion, or $3.28 a share, from $1.76 billion, or $1.95 a share, in the same period a year ago.
Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion
Eli Lilly on Thursday raised its annual profit forecast and sales of its popular weight-loss drug Zepbound crossed $1 billion for the first time in a quarter.
Here's Why Eli Lilly Stock Dropped 12% Last Month
A rival pharmaceutical company released promising clinical trial results from a weight-loss treatment. Eli Lilly is one of two companies dominating the obesity drug market right now.
Eli Lilly Reports Earnings Thursday Amid a Stock Slump
Investors will be looking for updates on Zepbound's rollout, and projections for when supply shortages in the U.S. might end.
Eli Lilly: Bearish Signals Loom Over Weight Loss Stock Ahead Of Q2 Earnings
Eli Lilly and Co LLY will be reporting its second-quarter earnings on Thursday. Wall Street expects $2.70 in EPS and $9.9 billion in revenues as the company reports before market hours.
